Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

NCT03450057 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.

NCT NCT03450057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03450057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment
Lead sponsor
Hellenic Society of Hematology
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2018
Completion date
March 22, 2021
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma